A carbonylation process for making acetic acid using a metallic co-catalyst composition, effective as a rhodium stabilizer and/or rate promoter, at molar ratios of metal/rhodium of about 0.5 to 40. The process includes reacting methanol with carbon monoxide in the presence of a rhodium-based catalytic metal complex with about 1 to 20 weight percent methyl iodide, less than about 8 weight % water and about 0.5 to about 30 weight percent methyl acetate. The crude acetic acid is flashed and further purified.

The amount of propionic acid produced in the process of oxidizing propane to acrylic acid is reduced by using a reactor with a length/diameter ratio >10 and/or maintaining the difference between the target reaction temperature and the peak temperature within the reactor to less than 20° C.

The present invention relates to a method for increasing L-methionine productivity and organic acid productivity. More particularly, the present invention relates to a method which involves adding a mixture containing methyl mercaptan and dimethyl sulfide at a appropriate ratio to O-acetyl homoserine or O-succinyl homoserine and to an enzyme having an activity of converting methionine precursor into L-methionine, so as to perform an enzyme reaction, to thereby improve the conversion rate of L-methionine and organic acid from the L-methionine precursor, and thus increasing L-methionine yield as compared to conventional method.

A process for preparing a pure alanylglutamine comprises the steps of: 1) reacting N-(α-chloro)-propionyl-glutamine and hydrazine compound to obtain an alanylglutamine crude product; 2) mixing anhydrous methanol and the alanylglutamine crude product to provide a filter cake; 3) dissolving the filter cake in water, heating, adding ethanol, and cooling to yield the pure alanylglutamine.

The present invention provides a method for purifying and recovering propionic acid from an aqueous mixture containing a fermentation product obtained from a fermentation process using glycerol as substrate, the method comprising optionally acidifying the aqueous mixture to a pH below 4.5, subjecting the aqueous mixture to an extraction with extracting agent containing a heavy extractant and optionally a light extractant as a diluent to obtain an extract comprising the extracting agent and organic acids, and a raffinate comprising water and any unreacted glycerol, and subjecting the extract to vacuum evaporation to separate propionic acid-containing organic acids from the extractant.

The present invention provides compounds for the inhibition of soluble epoxide hydrolase and associated disease conditions.

A method for producing acrylic acid and/or an ester thereof from a raw material composition containing hydroxypropionic acid and/or an ester thereof, the method including the steps of: (a) evaporating the raw material composition; and (b) dehydrating the evaporated raw material composition by contact with a dehydration catalyst, wherein the total amount of hydroxypropionic acid and/or an ester thereof supplied in the step (b) is controlled to be 70% by mass or more based on 100% by mass of the total amount of hydroxypropionic acid and/or an ester thereof supplied in the step (a).

A reactive rectification column suitable for the production of 2-hydroxy-4-methylmercaptobutyric acid and/or methionine contains a weir having a height of 100 mm or more.

A method of producing arginine bicarbonate is provided including reacting an arginine slurry with a source of carbon dioxide gas under elevated temperature and low pressure to form a solution of at least 50% arginine bicarbonate, and recovering arginine bicarbonate from the solution.

A process for producing (meth)acrylic acid comprising the step of repeating a crystallization operation “n” times to produce purified (meth)acrylic acid from crude (meth)acrylic acid, wherein: the each crystallization operation comprises a crystallizing step and a melting step; a polymerization inhibitor is not added to a (meth)acrylic acid melt obtained in the melting step of the first to n−1th crystallization operation(s) and a (meth)acrylic acid solution subjected to the crystallizing step of the second to nth crystallization operation(s); and a concentration of a polymerization inhibitor in a (meth)acrylic acid solution subjected to the crystallizing step of the first crystallization operation is adjusted so that a concentration of the polymerization inhibitor in a (meth)acrylic acid solution subjected to the crystallizing step of the nth crystallization operation is 2 ppm by mass or higher.

A method for preparing a high purity (e.g. greater than 70 wt. %) mono-hydrolyzed acyl halide compound as a precipitate from solution comprising the steps of preparing a solution comprising: i) at least 80 v/v % of a hydrocarbon solvent, ii) water at a molar concentration greater than its solubility limit within the solvent but less that its solubility limit in solution, iii) a tri-hydrocarbyl phosphate compound, and iv) a polyfunctional acyl halide compound at molar ratio to both water and the tri-hydrocarbyl phosphate compound of at least 1:1.

A composition for maintaining a function of platelets, the composition comprising, as an active ingredient, a compound represented by the following general formula (I) or a salt thereof, or a solvate thereof: wherein X represents a phenylene group;Y represents any one of a hydrogen atom and —(CH2)mR1;wherein m represents an integer of any one of 0 to 4; andR1 is any one of —NR5COR2, —NR5SO2R2, and —NR3R4;wherein R2 represents any one of a C1 to C6 alkyl group, an aryl group, a C1 to C6 alkoxy group, and the like;R3 and R4 represent a C1 to C6 alkyl group or the like; andR5 represents any one of a hydrogen atom, a C1 to C6 alkyl group, and the like; and Z represents any one of a hydrogen atom and a C1 to C6 alkyl group.

Disclosed herein are forms of L-ornithine phenyl acetate and methods of making the same. A crystalline form may, in some embodiments, be Forms I, II, III and V, or mixtures thereof. The crystalline forms may be formulated for treating subjects with liver disorders, such as hepatic encephalopathy. Accordingly, some embodiments include formulations and methods of administering L-ornithine phenyl acetate.

A method of making modified carbon materials for use in fabricating fuel cell components. The modified carbon may comprise pendant fluorocarbon groups bonded covalently bonded thereto. In one embodiment, a mixture is formed and comprises carbon material suitable for use in a fuel cell component, an organic solvent, a compound having the general formula I—R wherein R is a fluorocarbon, and a reductant.

In a process for removing aromatic carboxylic acid from a slurry thereof in solvent, the slurry is split into sub streams and each of said sub streams is supplied to a respective rotary pressure filter such that the sub stream pass through the filters in parallel. Gas is passed through the rotary pressure filters in series in an open-loop arrangement.

The present invention relates to methods for safe and efficient use of hydrogen and oxygen in ozonolysis operations. The invention also relates to an ozonolysis process involving elements of both reductive and oxidative ozonolysis which are integrated in a continuous process. In one embodiment, the ozonolysis process of the present invention uses hydrogen and/or oxygen generated from water and electricity, which may be recycled to generate water and/or electricity.

A process for producing unsaturated carboxylic acids or unsaturated nitriles by vapor phase oxidation reaction of their corresponding C3 to C5 alkanes, C3 to C5 alkenes, and mixtures thereof, as a hydrocarbon starting material, wherein the process performance is monitored and the path of gasses through catalyst beds is altered. Improved catalyst lifetimes may be achieved.

Methods of producing arginine bicarbonate solutions in very high concentrations including reacting an arginine slurry containing a first portion of arginine with a source of carbon dioxide gas at elevated pressure and temperature, adding subsequent portions of arginine to the resulting solution and further reacting with compressed carbon dioxide until a final solution containing in excess of 50% by weight are provided which include preparing an arginine solution by subjecting an arginine water slurry to elevated pressure and temperature and reacting the arginine solution with a source of carbon dioxide gas to form a solution comprising arginine and bicarbonate anion and recovering arginine bicarbonate from the solution.

Processes are disclosed for the conversion of 1,6-hexanediol to adipic acid employing a chemocatalytic reaction in which 1,6-hexanediol is reacted with oxygen in the presence of particular heterogeneous catalysts including at least one of platinum or gold. The metals are preferably provided on a support selected from the group of titania, stabilized titania, zirconia, stabilized zirconia, silica or mixtures thereof, most preferably zirconia stabilized with tungsten. The reaction with oxygen is carried out at a temperature from about 100° C. to about 300° C. and at a partial pressure of oxygen from about 50 psig to about 2000 psig.

Provided are processes for producing high-purity succinic acid from a succinic-acid-containing liquid through crystallization.

The polycyclic organic compounds which are substantially transparent for an electromagnetic radiation in the visible spectral range, an anisotropic optical film comprising at least one polycyclic organic compound and a method of producing thereof are disclosed. The polycyclic organic compounds have a general formula (I) wherein A and B are acid groups, n is the number of phenyl rings in the range from 3 to 10; m is 0, 1, 2 or 3; l is 1, 2, or 3, p is 1, 2, 3, 4, 5 or 6, C is a counterion from a list comprising H+, NH+4, Na+, K+, Li+, Cs+, Ca2+, Mg2+, Sr2+, La3+, Zn2+, Zr4+, Ce3+, Y3+, Yb3+, Gd3+, and any combination thereof; k is the number of counterions necessary for compensation of the negative electric charge equal to (−p).

A production process of a fluorosulfuric acid aromatic-ring ester according to the present invention includes reaction of an aromatic-ring hydroxyl compound with sulfuryl fluoride (SO2F2) in the presence of a tertiary amine except pyridine and methylpyridine. The sulfuryl fluoride, used as the reactant in the production process according to the present invention, is widely adapted as a fumigant and is easily available on a large scale. Further, the target compound can be obtained rapidly with a high yield under moderate reaction conditions in the production process according to the present invention. In this way, all of the prior art problems can be solved in the production process according to the present invention. The production process according to the present invention is thus particularly useful for industrial production of the fluorosulfuric acid aromatic-ring ester.

Various embodiments of the present invention generally disclose systems and processes for the conversion of a feed stream comprising at least one C8 aromatic into a product stream comprising isophthalic acid and purified terephthalic acid (IPA/TA).

An object of the present invention is to provide a substance characterized by ability to reduce oxidized coenzyme Q10 and ability to stabilize reduced coenzyme Q10, which contains nutrients, has a favorable taste, and is excellent in general versatility, and a method for using the same. The present invention relates to a method for producing reduced coenzyme Q10 comprising reducing oxidized coenzyme Q10 with a particular amino acid. The present invention also relates to a method for stabilizing reduced coenzyme Q10 in the presence of a particular amino acid and a composition stabilized by the method.

Disclosed is a process for the production and purification of glycolic acid or glycolic acid derivatives by the carbonylation of aqueous formaldehyde. The water in the hydrocarboxylation zone is reduced via reaction with the ester bonds in a recycle stream comprising glycolic acid oligomers and/or methyl glycolate oligomers.

The present invention provides a resin capable of contributing greatly to solve environmental problems and problems related to exhaustion of fossil fuel resources and having physical properties suited for practical use. The polyester according to the present invention has a diol and a dicarboxylic acid as constituent components and has an amount of terminal acid of 50 equivalents/metric ton or less.

The present invention concerns a TCTP antagonist, in particular a nucleic acid targeting an m RNA encoding Translationally-Controlled Tumor Protein (TCTP), wherein said nucleic acid is capable of reducing the amount of TCTP in cells, for use in the treatment or prevention of hormone-independent cancer or chemo-resistant cancer, such as an androgen-independent prostate cancer.

Provided herein are methods, compounds, and compositions for reducing expression of PTP1B mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate metabolic disease, for example, diabetes, or a symptom thereof.

A method of preparing the anthracyclin carminomycin using a starting material comprising daunorubicin. The method comprises reacting daunorubicin or N-protected daunorubicin with soft Lewis acids for the demethylation of the 4-methoxy group, resulting in a reaction mass. The reaction mass is treated with an aqueous solution of a strong organic acid or a mineral acid. After decomposition of the resulting carminomycin and Lewis acids reactive complex, the reaction mass is extracted using a water insoluble organic solvent. As a result, carminomycin is extracted as a base.

A pharmaceutical composition comprising lectins is anti-tumorigenic and anti-viral, bacterial or protozoan. The composition, termed BiOmune is also useful for imaging, diagnosis and therapy of cancer.

The present invention relates functional ligands to target molecules, particularly to functional nucleic acids and modifications thereof, and to methods for simultaneously generating, for example, numerous different functional biomolecules, particularly to methods for generating numerous different functional nucleic acids against multiple target molecules simultaneously. The present invention further relates to functional ligands which bind with affinity to target molecules. The present invention further relates to methods for generating, for example, functional biomolecules, particularly to functional nucleic acids, that bind with functional activity to another biomolecule, such as a receptor molecule. More than one or multiple targets as used herein may generally include different types of targets, and/or may also include a multitude of a singular type of targets at different conditions, such as, for example, temperature, pH, chemical environment, and/or any other appropriate conditions.

The invention describes new structures of the nucleotide conjugates (nuc-macromolecules) comprising at lease one nucleotide moiety coupled to at least one macromolecular compound via a short linker. These conjugates can be used as substrates for various kinds of polymerizing enzymes in the enzymatic synthesis of nucleic acids. In particular, these compounds can be used for labeling nucleic acids.

Disclosed herein are methods and reagents for determining the responsiveness of cancer to an epidermal growth factor receptor (EGFR) targeting treatment. The detection of these mutations will allow for the administration of gefitinib, erlotinib and other tyrosine kinase inhibitors to those patients most likely to respond to the drug.

The present invention provides compositions comprising therapeutic nucleic acids such as interfering RNA (e.g., dsRNA such as siRNA) that target SMAD4 gene expression, lipid particles comprising one or more (e.g., a cocktail) of the therapeutic nucleic acids, methods of making the lipid particles, and methods of delivering and/or administering the lipid particles (e.g., for treating anemia of inflammation in humans).

An antisense molecule capable of binding to a selected target site to induce exon skipping in the dystrophin gene, as set forth in SEQ ID NO: 1 to 202.

This invention relates to a process for preparing an oligonucleotide 5'-triphosphate. The process comprises the steps of: (a) synthesizing an oligonucleotide having a 5' hydroxyl moiety; (b) reacting the 5' hydroxyl moiety with a reagent of formula I: to convert the 5' hydroxyl moiety to a 5'-H-phosphonate, wherein R1 and R2 are each independently selected from the group consisting of haloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, cycloalkyl, substituted cycloalkyl, heterocycle, and substituted heterocycle, acyl, phosphoryl, substituted alkyl acyl, substituted heteroalkyl acyl, substituted aryl acyl or substituted heteroaryl acyl, substituted alkyl phosphoryl, substituted heteroalkyl acyl, substituted aryl phosphoryl, and substituted heteroaryl phosphoryl; (c) activating the H-phosphonate of step (b) by reacting the H-phosphonate with a silylating agent, a halogenated oxidizing agent, a nitrogen-containing heteroaryl, or a combination thereof, to form an activated H-phosphonate; and (d) treating the oligonucleotide having an activated H-phosphonate from step (c) with a poly(alkylammonium)pyrophosphate.

The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.

Disclosed is a method of preparing cationic starch. The method includes preparing a starch suspension containing a cationization agent; performing ultrahigh pressure treatment on the starch suspension; and obtaining cationic starch from the starch suspension subjected to ultrahigh pressure treatment.

The present invention is directed to L-proline and citric acid co-crystals of (2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol, pharmaceutical compositions containing said co-crystals and their use in the treatment glucose-related disorders such as Type 2 diabetes mellitus and Syndrome X.

Described is a microfluidic process for manufacturing partially cross-linked alginate solution, wherein the alginate solution is a homogenous liquid which exhibits an elastic response (G') which is equal to or greater than its viscous response (G″). In particular, the process may comprise microfluidic mixing of sodium alginate and calcium gluconate solutions to provide an injectable partially cross-linked alginate solution.

The invention refers to polynucleotides selected from the group consisting of a) polynucleotides encoding for the polypeptide RBM20 comprising a P638L mutation for a human polypeptide RBM20, or a P641L mutation for a rat polypeptide RBM20, b) polynucleotides with a reverse complementary sequence of the polynucleotide of a) above, and c) polynucleotides with an identity at least 50% to a polynucleotide of a) or b) above.

The present disclosure relates to non-naturally occurring polypeptides useful for preparing Ezetimibe, polynucleotides encoding the polypeptides, and methods of using the polypeptides.

A recombinant micro-organism producing resveratrol by a pathway in which phenylalanine ammonia lyase (PAL) produces trans-cinnamic acid from phenylalanine, cinnamate 4-hydroxylase (C4H) produces 4-coumaric acid from said trans-cinnamic acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA, or in which L-phenylalanine- or tyrosine-ammonia lyase (PAL/TAL) produces 4-coumaric acid, 4-coumarate-CoA ligase (4CL) produces 4-coumaroyl CoA from said 4-coumaric acid, and resveratrol synthase (VST) produces said resveratrol from said 4-coumaroyl CoA. The micro-organism may be a yeast, fungus or bacterium including Saccharomyces cerevisiae, E. coli, Lactococcus lactis, Aspergillus niger, or Aspergillus oryzae.

An α-amylase from Bacillus subtilis (AmyE) produces significant amounts of glucose from various carbohydrate substrates, including vegetable starch, maltoheptaose, and maltotriose. Among other things, this advantageous property allows AmyE or variants thereof to be used in a saccharification reaction having a reduced or eliminated requirement for glucoamylase. The reduction or elimination of the glucoamylase requirement significantly improves the efficiency of the production of ethanol or high fructose corn syrup, for example.

A cytosine analog, a method of preparation of a cytosine analog, a DNA methyltransferase 1 inhibitor, and a method for DNA methylation inhibition, is provided for the treatment of diseases associated with deviations from normal DNA methylation. The analog of cytosine may be comprised of 1, N4, 5 and 6-substituted derivatives of cytosine or 5,6-dihydrocytosine, wherein the analog can be described by the chemical formula where R1 is H, R3, R4, 2'-deoxyribosyl, R4 is alkyl or aryl, X is N or C, wherein if X in the analog of formula I is N, then R5 is no substituent and if X in the analog of formula I and/or II is C or if X in the analog of formula II is N, then R5 and R6 are independently alkyl, aryl, hydroxyalkyl, aminoalkyl, hydroxyl, carboxyl, amino group, alkoxyl, aryloxyl, aminoalkyl, aminoaryl, thio group, sulfonyl, sulfinyl or halogen.

The present invention relates to oligomer compounds (oligomers) for the treatment and prevention of acute myeloid leukemia, which target GLI2 mRNA in a cell, leading to reduced expression of GLI2.

RNA interference is provided for inhibition of Frizzled Related Protein-1 mRNA expression, in particular, for treating patients having glaucoma or at risk of developing glaucoma.

The present invention relates to the field of cardiology. More specifically, the present invention provides methods and compositions for inducing proliferation of cardiomyocytes. In a specific embodiment, a method for inducing proliferation of cardiomyocytes comprises the step of administering an effective amount of an ALMS1 inhibitor.

The present invention relates to novel 1,2,3-triazolyl purine derivatives. The invention also relates to using the derivatives to treat cancer and various viral infections. An example of a 1,2,3-triazolyl purine derivative of the invention is

Provided herein are compounds used to inhibit the deamination enzyme responsible for the inactivation of therapeutic compounds, and methods of using them.